To assess the rates of myasthenic crisis, exacerbations and hospitalizations/emergency room (ER) visits among US patients with generalized myasthenia gravis (gMG) treated with eculizumab, a complement component C5 inhibitor, in clinical practice.
No takes yet. Share an insight, caveat, or question.
Tandan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: